Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olaparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 1/20 | 1.00 |
| ▸ | PARP3 known ✓ | Q9Y6F1 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 1/20 | 1.00 |
| ▸ | PARP14 | Q460N5 | 1/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 1.00 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 1.00 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 1.00 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 1.00 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 1.00 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 1.00 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olaparib SCHEMBL29352148 | 1.00 | PARP1 (1.00) | PARP1TNKSADORA1CDK6PDE3A | |
| Olaparib SCHEMBL426568 | 1.00 | PARP1 (1.00) | PARP1TNKSADORA1CDK6PDE3A | |
| Olaparib SCHEMBL28083947 | 0.96 | PARP1 (0.93) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL22852727 | 0.96 | PARP1 (0.98) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL28732627 | 0.95 | PARP1 (0.91) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL22829780 | 0.94 | PARP1 (1.00) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL19569971 | 0.92 | PARP1 (0.90) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL22852988 | 0.91 | PARP1 (0.89) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL9280839 | 0.91 | PARP1 (0.83) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL15846235 | 0.91 | PARP1 (0.83) | PARP1TNKSADORA1CDK6PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118284433-A | Method for treating cancers with dual allele loss of function or gene overexpression mutations | 修复治疗公司 | 2024-07-02 | — | — | CN | claimed |
| CN-117500506-A | Use of ATR inhibitors in combination with PARP inhibitors for the treatment of cancer | 修复治疗公司 | 2024-02-02 | — | — | CN | claimed |
| CN-112675174-B | New use of poly ADP ribose polymerase inhibitor for treating hepatitis B virus related diseases | 四川大学华西第二医院 | 2022-06-17 | — | — | CN | claimed |
| CN-122055153-A | EGFR inhibitors for treating EGFR exon 20 mutation positive lung cancer | 安塔列斯疗法股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-120590386-A | Quinoxaline protein degradation agent, and preparation method and application thereof | 北京科莱博医药开发有限责任公司 | 2025-09-05 | — | — | CN | disclosed |
| CN-120157657-A | Phthalazinone compound containing piperazinone, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2025-06-17 | — | — | CN | disclosed |
| CN-110787285-B | XBP1, CD138 and CS1 peptides, pharmaceutical compositions comprising the peptides, and methods of using the peptides and compositions | 达纳-法伯癌症研究所股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120019055-A | Salt and crystal form of heterocyclic derivative inhibitor, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119970722-A | Application of verteporfin in preparation of anti-colorectal cancer drugs | 上海交通大学医学院附属仁济医院 | 2025-05-13 | — | — | CN | disclosed |
| CN-115806526-B | In Olaparib Process for the preparation of intermediates | 上海博邦医药科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119894872-A | Heteroarenes, pharmaceutical compositions containing heteroarenes, and methods of use thereof | 修复治疗公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-112675174-B | New use of poly ADP ribose polymerase inhibitor for treating hepatitis B virus related diseases | 四川大学华西第二医院 | 2022-06-17 | — | — | CN | disclosed |
| EP-3998347-A1 | NOVEL MARKERS FOR DETECTING MICROSATELLITE INSTABILITY IN CANCER AND DETERMINING SYNTHETIC LETHALITY WITH INHIBITION OF THE DNA BASE EXCISION REPAIR PATHWAY | VIB VZW (BE) | 2022-05-18 | — | — | EP | disclosed |
| CN-110088098-B | Quinazolinone PARP-1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-04-15 | — | — | CN | disclosed |
| CN-112979557-B | Novel synthesis method of Olaparib bulk drug | 南京亿华药业有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114075159-A | Purification method and application of olapari | 吉林汇康制药有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-114075143-A | Preparation method of olaparide and intermediate thereof | 吉林汇康制药有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-114053276-A | Application of intermediate TSL-1502M of PARP inhibitor TSL-1502 | 江苏天士力帝益药业有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-114053271-A | Pharmaceutical composition containing TSL-1502M and application thereof | 江苏天士力帝益药业有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-109232575-B | Pyrrole [1,2-b ] pyridazine compound or pharmaceutically acceptable salt thereof and application thereof | 中国科学院上海药物研究所 | 2022-01-25 | — | — | CN | disclosed |